TriangleRuxolitinib + Venetoclax (NCT03874052)
Ruxolitinib + Venetoclax trial for Relapsed/Refractory Acute Myeloid Leukemia (NCT03874052). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for acute myeloid leukemia that has returned or has not responded to treatment, in adults.
The idea: add ruxolitinib to venetoclax. One group receives ruxolitinib with venetoclax. Another group also receives azacitidine. The drugs are given in 28 day cycles. Ruxolitinib may stop cancer cell growth by blocking enzymes cells need to grow.
This phase 1 study looks for the maximum tolerated dose of ruxolitinib in each combination, and plans 51 patients. At OHSU Knight Cancer Institute in Portland, Oregon, Jennifer Saultz leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.